Krys Corbett has over two decades of experience with transactions, partnerships and cross-functional teams in biopharma. She was previously General Counsel and Head of Business Development at ORIC Pharmaceuticals. Prior to that, at Roche and at Genentech she was responsible for key collaborations including those covering Venclexta, Lucentis, Xolair, Avastin, Herceptin and Rituxan. She also led transactions and teams for new product and life cycle opportunities. Ms. Corbett started her career at Wilson Sonsini and is a graduate of Duke Law School.